Liponex CRD5 results boosted by PPIs

Liponex Inc. reports that one in five patients taking the lower trial dose of drug CRD5 saw their “good cholesterol” rise more than 10%. The biopharmaceutical company is engaged in Phase I/II clinical trials for its lead drug candidate, which is being developed to treat heart disease and increase high-density lipoprotein (good cholesterol) levels in the body. The company is encouraged by the effects of proton pump inhibitors (PPI), which reduce gastric acid in CRD5 patients taking PPI drugs such as Zantac or Prevacid. Liponex says it will continue to work on CRD5’s sensitivity to pH levels and expects to have results from another clinical trial in the first quarter of 2008. In March, Liponex’ shares took a bashing after the company announced disappointing CRD5 trial results. During the previous four months, the company’s stock shot up 250% after Pfizer halted trials of torcetrapib, putting CRD5 at the front of the race to be the first good cholesterol-promoting drug on the market.

Submit a comment

Please leave your name, which will be used to sign your submission to the SCANsite. Thanks for contributing your thoughts. Come back again. Tony Patterson, Editor & CEO.

© 2006 - 2009 SCAN
INTEGRITY INTELLIGENCE INFORMATION
Site by Citadel Rock
SCAN